Mentice (publ), Gothenburg, a world leader in simulation solutions for image-guided interventional therapies, today published its Annual Report and Sustainability Report 2023.

2023 - A good year and a solid foundation for continued growth

• Net sales increased by more than 25 per cent.
• Strong market development in North America.
• Important certificates secured and strategic acquisition of Biomodex.

Read more about Mentice’s operations, markets, and strategy going forward.

The Annual Report 2023 is available to shareholders and other interested parties at investor.mentice.com/financial-reports-and-presentations/mentice-annual-report-2023. A printed copy can be obtained upon written request to stacy.hammar@mentice.com.

For more information, please contact:
Göran Malmberg, CEO, Mentice
E-post: goran.malmberg@mentice.com
US Mobile. +1 (312) 860 5610
Sweden Mobile +46 (0) 703 09 22 22

About Mentice
Mentice (STO: MNTC) is the world leader in proficiency based simulation solutions for image guided interventional therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are just some of the clinical areas covered by our solutions. Learn more about the features and benefits of Mentice solutions at: www.mentice.com

Marketplace| Nasdaq First North Growth Market, Stockholm | Ticker symbol MNTC
Certified Adviser| FNCA Sweden AB

Image Attachments
AR 2023 IMG

Attachments
Annual Report 2023 Mentice